3-n-methylspiperone has been researched along with perospirone in 1 studies
Studies (3-n-methylspiperone) | Trials (3-n-methylspiperone) | Recent Studies (post-2010) (3-n-methylspiperone) | Studies (perospirone) | Trials (perospirone) | Recent Studies (post-2010) (perospirone) |
---|---|---|---|---|---|
155 | 6 | 7 | 111 | 24 | 26 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Iwata, Y; Minabe, Y; Mori, N; Nakamura, K; Okada, H; Ouchi, Y; Sekine, Y; Sugihara, G; Suzuki, K; Takei, N; Tsuchiya, KJ; Yoshikawa, E | 1 |
1 trial(s) available for 3-n-methylspiperone and perospirone
Article | Year |
---|---|
Perospirone is a new generation antipsychotic: evidence from a positron emission tomography study of serotonin 2 and D2 receptor occupancy in the living human brain.
Topics: Adult; Antipsychotic Agents; Binding, Competitive; Brain; Humans; Indoles; Isoindoles; Male; Positron-Emission Tomography; Raclopride; Radiopharmaceuticals; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT2; Reference Values; Spiperone; Thiazoles | 2006 |